In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novo Nordisk licenses Emisphere's eligen technology

Executive Summary

Novo Nordisk AS licensed rights to drug delivery company Emisphere Technologies' eligen carrier technology for use in developing oral versions of its glucagon-like peptide 1 (GLP-1) receptor agonists for Type II diabetes.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register